Relevance of commensal microbiota in the treatment and prevention of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2478-2489

  Dasgupta, Suryasarathi ^a   Kasper, Dennis L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Commensal microbiota; Immunoregulation; Inflammatory bowel disease; Microbiota in patients

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOSUPPRESSIVE AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT;

BACTEROIDES FRAGILIS; COMMENSAL; DENDRITIC CELL; ENTERITIS; FECES; FECES MICROFLORA; HUMAN; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; BACTERIA; HUMANS; INFLAMMATORY BOWEL DISEASES; MICROBIOTA;

EID: 84888252464     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318297d884     Document Type: Review

References (136)

1. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.
2. Mitsou EK, Kirtzalidou E, Oikonomou I, et al. Fecal microflora of Greek healthy neonates. Anaerobe. 2008;14:94-101.
3. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685-693.
4. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-1023.
5. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444:1027-1031.
6. Albenberg LG, Lewis JD, Wu GD. Food and the gut microbiota in inflammatory bowel diseases: A critical connection. Curr Opin Gastroenterol. 2012;28:314-320.
7. Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9:577-589.
8. Boirivant M, Amendola A, Butera A. Intestinal microflora and immunoregulation. Mucosal Immunol. 2008;1(Suppl 1):S47-S49.
9. von Boehmer H. Oral tolerance: Is it all retinoic acid J Exp Med. 2007; 204:1737-1739.
10. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337-341.
11. Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107-118.
12. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620-625.
13. Ochoa-Reparaz J, Mielcarz DW, Ditrio LE, et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J Immunol. 2010;185: 4101-4108.
14. Troy EB, Carey VJ, Kasper DL, et al. Orientations of the Bacteroides fragilis capsular polysaccharide biosynthesis locus promoters during symbiosis and infection. J Bacteriol. 2010;192:5832-5836.
15. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332: 974-977.
16. An D, Na C, Bielawski J, et al. Membrane sphingolipids as essential molecular signals for Bacteroides survival in the intestine. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4666-4671.
17. Himmel ME, Yao Y, Orban PC, et al. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012;136: 115-122.
18. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 2006;116:1713-1722.
19. McMurchy AN, Di Nunzio S, Roncarolo MG, et al. Molecular regulation of cellular immunity by FOXP3. Adv Exp Med Biol. 2009;665:30-46.
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
21. Huber S, Gagliani N, Espligues E, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34:554-565.
22. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28:546-558.
23. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566-569.
24. Konkel JE, Chen W. Balancing acts: the role of TGF-beta in the mucosal immune system. Trends Mol Med. 2011;17:668-676.
25. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
26. Holmen N, Lundgren A, Lundin S, et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006;12:447-456.
27. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007;13:191-199.
28. Reikvam DH, Perminow G, Lyckander LG, et al. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohns disease patients. Scand J Gastroenterol. 2011;46:550-560.
29. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graftversus-host disease. Am J Transplant. 2011;11:1148-1157.
30. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757-1764.
31. DePaolo RW, Abadie V, Tang F, et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature. 2011;471:220-224.
32. Laffont S, Siddiqui KR, Powrie F. Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells. Eur J Immunol. 2010;40:1877-1883.
33. Siddiqui KR, Laffont S, Powrie F. E-cadherin marks a subset of inflammatory dendritic cells that promote T cell-mediated colitis. Immunity. 2010;32:557-567.
34. Iliev ID, Mileti E, Matteoli G, et al. Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. Mucosal Immunol. 2009;2:340-350.
35. Matteoli G, Mazzini E, Iliev ID, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59:595-604.
36. Hadeiba H, Sato T, Habtezion A, et al. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versushost disease. Nat Immunol. 2008;9:1253-1260.
37. Lombardi V, Speak AO, Kerzerho J, et al. CD8alpha(+)beta(-) and CD8alpha(+)beta(+) plasmacytoid dendritic cells induce Foxp3(+) regulatory T cells and prevent the induction of airway hyper-reactivity. Mucosal Immunol. 2012;5:432-443.
38. Irla M, Kupfer N, Suter T, et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J Exp Med. 2010;207:1891-1905.
39. Galicia-Rosas G, Pikor N, Schwartz JA, et al. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J Immunol. 2012;189: 3700-3706.
40. Goubier A, Dubois B, Gheit H, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 2008;29:464-475.
41. Hadeiba H, Lahl K, Edalati A, et al. Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity. 2012;36:438-450.
42. Hardenberg G, Steiner TS, Levings MK. Environmental influences on T regulatory cells in inflammatory bowel disease. Semin Immunol. 2011; 23:130-138.
43. Cassani B, Villablanca EJ, De Calisto J, et al. Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med. 2012;33:63-76.
44. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006; 212:28-50.
45. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004;10:620-625.
46. Lindsay J, Van Montfrans C, Brennan F, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther. 2002;9:1715-1721.
47. Polyak S, Mach A, Porvasnik S, et al. Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2012; 302:G296-G308.
48. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohns disease. Clin Gastroenterol Hepatol. 2006;4:754-759.
49. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-1725.
50. Brand S. Crohns disease: Th1, Th17 or both The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohns disease. Gut. 2009;58:1152-1167.
51. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010;30:80-89.
52. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423-7430.
53. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
54. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
55. Heller F, FLorian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
56. Saleh M, Elson CO. Experimental inflammatory bowel disease: Insights into the host-microbiota dialog. Immunity. 2011;34:293-302.
57. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999;44:812-818.
58. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease. J Exp Med. 1998;187:855-864.
59. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
60. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485-498.
61. Lee YK, Menezes JS, Umesaki Y, et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4615-4622.
62. Loh G, Blaut M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 2012;3:544-555.
63. Rehman T. Role of the gut microbiota in age-related chronic inflammation. Endocr Metab Immune Disord Drug Targets. 2012;12:361-367.
64. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62:531-539.
65. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature. 2012;487:104-108.
66. Carbonero F, Benefiel AC, Gaskins HR. Contributions of the microbial hydrogen economy to colonic homeostasis. Nat Rev Gastroenterol Hepatol. 2012;9:504-518.
67. Dasgupta S, Kasper DL. Novel tools for modulating immune responses in the host-polysaccharides from the capsule of commensal bacteria. Adv Immunol. 2010;106:61-91.
68. Carvalho FA, Koren O, Goodrich JK, et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe. 2012;12:139-152.
69. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012; 487:477-481.
70. Comito D, Romano C. Dysbiosis in the pathogenesis of pediatric inflammatory bowel diseases. Int J Inflamm. 2012;2012:687143.
71. Cucchiara S, Stronati L, Aloi M. Interactions between intestinal microbiota and innate immune system in pediatric inflammatory bowel disease. J Clin Gastroenterol. 2012;46(Suppl):S64-S66.
72. Schippa S, Iebba V, Totino V, et al. A potential role of Escherichia coli pathobionts in the pathogenesis of pediatric inflammatory bowel disease. Can J Microbiol. 2012;58:426-432.
73. Ricanek P, Lothe SM, Frye SA, et al. Gut bacterial profile in patients newly diagnosed with treatment-naive Crohns disease. Clin Exp Gastroenterol. 2012;5:173-186.
74. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178-184.
75. Ananthakrishnan AN. Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:339-353.
76. Navaneethan U, Mukewar S, Venkatesh PG, et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6:330-336.
77. Sonnenberg A, Mukewar S, Venkatesh PG, Genta RM. Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:469-476.
78. Antonelli E, Baldoni M, Giovenali P, et al. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohns Colitis. 2012;6: 154-159.
79. Masclee GM, Penders J, Pierik M, et al. Enteropathogenic viruses: triggers for exacerbation in IBD A prospective cohort study using real-time quantitative polymerase chain reaction. Inflamm Bowel Dis. 2013;19: 124-131.
80. Brito F, Zaltman C, Carvalho AT, et al. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. Eur J Gastroenterol Hepatol. 2013;25:239-245.
81. Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G675-G685.
82. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation Am J Gastroenterol. 2012;107:1755.
83. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9:88-96.
84. Damman CJ, Miller SI, Surawicz CM, et al. The microbiome and inflammatory bowel disease: Is there a therapeutic role for fecal microbiota transplantation Am J Gastroenterol. 2012;107:1452-1459.
85. Rubin TA, Gessert CE, Aas J, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013;19:22-26.
86. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012;5:403-420.
87. Shahinas D, Silverman M, Sittler T, et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio. 2012;3:e00338-12.
88. Zainah H, Silverman A. Fecal bacteriotherapy: A case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis. 2012;2012:810943.
89. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145-149.
90. El-Matary W, Simpson R, Ricketts-Burns N. Fecal microbiota transplantation: Are we opening a can of worms Gastroenterology. 2012;143:e19; author reply e19-e20.
91. Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131:33-45.
92. Garrett WS, Gallini CA, Yasunenko T, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe. 2010;8:292-300.
93. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145:745-757.
94. Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4:337-349.
95. Forsythe P, Bienenstock J. Immunomodulation by commensal and probiotic bacteria. Immunol Invest. 2010;39:429-448.
96. Foligne B, Peys E, Vanderkerckhove J, et al. Spores from two distinct colony types of the strain Bacillus subtilis PB6 substantiate anti-inflammatory probiotic effects in mice. Clin Nutr. 2012;31:987-994.
97. Leber B, Tripolt NJ, Blattl D, et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study. Eur J Clin Nutr. 2012;66:1110-1115.
98. Gobel RJ, Larsen N, Jakobsen M, et al. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J Pediatr Gastroenterol Nutr. 2012;55:673-678.
99. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012; 35:327-334.
100. Daniluk U, Alifier M, Kaczmarski M. Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract. Adv Med Sci. 2012;57:175-182.
101. Yan F, Polk DB. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes. 2012;3:25-28.
102. Yan F, Cao H, Cover TL, et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology. 2007;132:562-575.
103. Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohns disease Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453-457.
104. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohns disease. Inflamm Bowel Dis. 2005;11:833-839.
105. Guzy C, Paclik D, Schirbel A, et al. The probiotic Escherichia coli strain Nissle 1917 induces gammadelta T cell apoptosis via caspase-and FasLdependent pathways. Int Immunol. 2008;20:829-840.
106. Soderstrom K, Bucht A, Halapi E, et al. Increased frequency of abnormal gamma delta T cells in blood of patients with inflammatory bowel diseases. J Immunol. 1996;156:2331-2339.
107. Bassaganya-Riera J, Viladomiu M, Pedragosa M, et al. Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR gamma to suppress colitis. PLoS One. 2012;7:e31238.
108. DSouza A, Cai CL, Kumar D, et al. Cytokines and Toll-like receptor signaling pathways in the terminal ileum of hypoxic/hyperoxic neonatal rats: benefits of probiotics supplementation. Am J Transl Res. 2012;4: 187-197.
109. Jonkers D, Penders J, Masclee A, et al. Probiotics in the management of inflammatory bowel disease: A systematic review of intervention studies in adult patients. Drugs. 2012;72:803-823.
110. Hummel S, Veltman K, Cichon C, et al. Differential targeting of the E-Cadherin/beta-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. Appl Environ Microbiol. 2012;78: 1140-1147.
111. Patel RM, Myers LS, Kurundkar AR, et al. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol. 2012;180:626-635.
112. Zakostelska Z, Kverka M, Klimesova K, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011;6:e27961.
113. Ueno N, Fujiya M, Segawa S, et al. Heat-killed body of Lactobacillus brevis SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function. Inflamm Bowel Dis. 2011; 17:2235-2250.
114. Oliveira M, Bosco N, Perruisseau G, et al. Lactobacillus paracasei reduces intestinal inflammation in adoptive transfer mouse model of experimental colitis. Clin Dev Immunol. 2011;2011:807483.
115. Petersen ER, Claesson MH, Schmidt EG, et al. Consumption of probiotics increases the effect of regulatory T cells in transfer colitis. Inflamm Bowel Dis. 2012;18:131-142.
116. Takamura T, Harama D, Fukumoto S, et al. Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol Cell Biol. 2011;89:817-822.
117. Gruber L, Lichti P, Rath E, et al. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol. 2012;46:735-747.
118. Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012;56: 524-535.
119. Sangwan V, Tomar SK, Singh RR, et al. Galactooligosaccharides: novel components of designer foods. J Food Sci. 2011;76:R103-R111.
120. Wong CC, Zhang L, Li ZJ, et al. Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. J Gastroenterol Hepatol. 2012;27:1205-1212.
121. LeBlanc JG, del Carmen S, Miyoshi A, et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohns disease in mice. J Biotechnol. 2011;151:287-293.
122. Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity. 2008;29:637-649.
123. von Schillde MA, Hormannsperger G, Weiher M, et al. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe. 2012;11: 387-396.
124. Liu WS, Chen MC, Chiu KH, et al. Amelioration of dextran sodium sulfate-induced colitis in mice by Rhodobacter sphaeroides extract. Molecules. 2012;17:13622-13630.
125. Bernardo D, Sanchez B, Al-Hassi HO, et al. Microbiota/host crosstalk biomarkers: regulatory response of human intestinal dendritic cells exposed to Lactobacillus extracellular encrypted peptide. PLoS One. 2012;7:e36262.
126. Wang Q, McLoughlin RM, Cobb BA, et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor. J Exp Med. 2006;203:2853-2863.
127. Cobb BA, Wang Q, Tzianabos AO, et al. Polysaccharide processing and presentation by the MHCII pathway. Cell. 2004;117:677-687.
128. Duan J, Avci FY, Kasper DL. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc Natl Acad Sci U S A. 2008;105:5183-5188.
129. Ochoa-Reparaz J, Mielcarz DW, Wang Y, et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3:487-495.
130. Chung H, Pamp SJ, Hill JA, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149:1578-1593.
131. Mercer M, Brinich MA, Geller G, et al. How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol. 2012;46: 138-144.
132. Adham K, Dougherty T, Sardana N, et al. Buyer beware: therapeutic claims of probiotics marketed to Crohns disease patients via the internet lack supporting data. Inflamm Bowel Dis. 2012;18:597.
133. Adham K, Dougherty T, Sardana N, et al. Search with caution: Internet sites target pediatric Crohns patients with probiotics that often claim to be curative. Inflamm Bowel Dis. 2012;18:596.
134. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338:120-123.
135. Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012;150: 470-480.
136. Naik S, Bouladoux N, Wilhelm C, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337:1115-1119.